Walleye Trading LLC Chemo Centryx, Inc. Transaction History

Walleye Trading LLC

$46.7 Billion
Q3 2024

Shares

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $627,388 - $1.47 Million	28,299 Added 165.99%	45,348 $2.34 Million
Q2 2022 Aug 08, 2022	SELL	$15.36 - $27.51 $77,598 - $138,980	-5,052 Reduced 22.86%	17,049 $422,000
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $521,881 - $918,811	-23,487 Reduced 51.52%	22,101 $554,000
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $798,169 - $1.76 Million	43,426 Added 2008.6%	45,588 $1.66 Million
Q3 2020 Nov 16, 2020	BUY	$46.35 - $61.69 $100,208 - $133,373	2,162 New	2,162 $118,000
Q2 2019 Aug 14, 2019	SELL	$8.31 - $14.85 $122,988 - $219,780	-14,800 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$10.01 - $13.89 $148,148 - $205,572	14,800 New	14,800 $206,000
Q2 2018 Aug 14, 2018	SELL	$10.62 - $13.98 $152,928 - $201,312	-14,400 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$5.9 - $14.99 $84,960 - $215,856	14,400 New	14,400 $196,000
Q3 2017 Nov 14, 2017	SELL	$6.5 - $10.69 $38,350 - $63,071	-5,900 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	5,900	5,900 $55,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.